# US 2025/0367658 A1 · Systems And Methods For Semi-Quantitative And Quantitative Detection Of Metabolities Of Progesterone

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367658 A1
- Document ID: US20250367658A1
- Status: Published application
- Kind: A1
- Application number: 19/221,402
- Filed: 2025-05-28
- Published: 2025-12-04
- Earliest claimed: 2024-05-28
- Assignees: Easy Healthcare Corporation
- Applicants: Easy Healthcare Corporation
- Inventors: Xiaolian Liu; Li Zou
- Web page: https://patentgrep.com/patent/US20250367658A1

## CPC

- B01L 3/5023: {with a sample being transported to, and subsequently stored in an absorbent for analysis}
- B01L 3/502715: {characterised by interfacing components, e.g. fluidic, electrical, optical or mechanical interfaces}
- G01N 21/78: producing a change of colour
- G01N 33/54388: {based on lateral flow}
- G01N 33/689: {related to pregnancy or the gonads}
- G01N 33/743: {Steroid hormones}
- B01L 2200/04: Exchange or ejection of cartridges, containers or reservoirs
- B01L 2200/148: Specific details about calibrations
- B01L 2300/0654: Lenses; Optical fibres
- B01L 2300/069: Absorbents; Gels to retain a fluid
- B01L: CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A test system includes a test device and a calibration chart. The test includes a lateral flow assay that detects the presence of a target analyte. In response to exposure to the target analyte, the results area produces a visually identifiable test-line and a visually identifiable control-line, wherein the visually identifiable test-line increases in darkness according to an increased concentration level of the target analyte. The calibration chart includes a plurality of color blocks, wherein each of the color blocks is representative of a test-line color density that corresponds to a quantitative hormone concentration in the target substance. The test system further includes a user device that derives a quantitative result, tracks the quantitative levels over the time, and compares them to normal hormone trends and threshold values associated with defined risk levels for certain health conditions.

## Claims

### Claim 1

A test system comprising:
a test device including a test area, a results area, and a control area, wherein the test area of the body includes a lateral flow assay that detects the presence of a target analyte in a target substance, wherein, in response to exposure to the target analyte, the results area produces a visually identifiable test-line having a test-line color density and a visually identifiable control-line having a control-line density, wherein the visually identifiable test-line increases in darkness according to an increased concentration level of the target analyte; and
a calibration chart including a plurality of color blocks, wherein each of the color blocks is representative of a test-line color density that corresponds to a quantitative hormone concentration in the target substance.

### Claim 2 (depends on 1)

The test system of claim 1, wherein the test area is a non-competitive lateral flow assay for determining the concentration of the target analyte, wherein the target analyte is one or more progesterone metabolite, including a pregnanediol such as PdG, pregnanolone, and pregnanetriol.

### Claim 3 (depends on 1)

The test system of claim 1, further comprising:
a user device including a camera, a processor, a display, and memory storing program instructions, wherein, in response to executing the program instructions, the processor:
receives an image of the test area from the camera, the image including the visually identifiable test-line and the visually identifiable control-line;
determines a test-line value defined as a numerical value of a color density of the test-line in the image;
determines a control-line value defined as a numerical value of a color density of the control-line in the image; and
calculates a quantitative hormone concentration in the target substance using the numerical value of the color density of the test-line in the image and the numerical value of the color density of the control-line in the image.

### Claim 4 (depends on 3)

The test system of claim 3, wherein calculating a quantitative hormone concentration in the target substance using the numerical value of the color density of the test-line in the image and the numerical value of the color density of the control-line in the image, includes:
calculating a T/C ratio defined as a relative value of the test-line value to the control-line value; and
determining a quantitative hormone level based on the comparison between the T/C ratio and a data structure that maps calibrated T/C ratios to quantitative hormone levels.

### Claim 5 (depends on 4)

The test system of claim 4, wherein, in response to executing the program instructions, the processor further presents visualized data through the display indicative of one or more T/C ratio trends or one or more quantitative hormone level trends.

### Claim 6 (depends on 1)

The test system of claim 1, further comprising a user device including a processor, a display, and memory storing program instructions, wherein, in response to executing the program instructions, the processor:
receives quantitative hormone levels at one or more specific stages of a menstrual cycle or a pregnancy derived from the test device and calibration chart; and
compares the quantitative hormone levels at one or more specific stages of a menstrual cycle or a pregnancy to one or more normal hormone level trends.

### Claim 7 (depends on 6)

The test system of claim 6, wherein the processor further compares the quantitative hormone levels at one or more specific stages of a menstrual cycle or a pregnancy to one or more threshold values associated with risk levels of certain health condition, wherein the one or more threshold values associated with risk levels of one or more health conditions are determined based on scientific research and data analysis in combination with a user's personalized data.

### Claim 8 (depends on 7)

The test system of claim 7, wherein the one or more health conditions include: a miscarriage, an ectopic pregnancy, an ovarian tumor, or an adrenal gland problem.

### Claim 9 (depends on 6)

The test system of claim 6, wherein the display provides an indication of a potential health condition risk derived from a comparison between the quantitative hormone levels at one or more specific stages of a menstrual cycle or a pregnancy derived from the test device and calibration chart and one or more normal hormonal level trends.

### Claim 10

A test system comprising:
a test device including a test area, a results area, and a control area, wherein the test area of the body includes a lateral flow assay that detects the presence of a target analyte in a target substance, wherein, in response to exposure to the target analyte, the results area produces a visually identifiable test-line having a test-line color density and a visually identifiable control-line having a control-line density, wherein the visually identifiable test-line increases in darkness according to an increased concentration level of the target analyte; and
a user device including a camera, a processor, a display, and memory storing program instructions, wherein, in response to executing the program instructions, the processor:
receives an image of the test area from the camera, the image including the visually identifiable test-line and the visually identifiable control-line;
determines a test-line value defined as a numerical value of the test-line color density;
determines a control-line value defined as a numerical value of the control-line color density;
calculates a T/C ratio defined as a relative value of the test-line value to the control-line value; and
determines a quantitative hormone level based on the comparison between the T/C ratio and a data structure that maps calibrated T/C ratios to quantitative hormone levels.

### Claim 11 (depends on 10)

The test system of claim 10, further wherein the processor presents visualized data through the display indicative of one or more T/C ratio trends or one or more quantitative hormone level trends.

### Claim 12 (depends on 10)

The test system of claim 10, wherein the T/C ratios or the quantitative hormone levels at one or more specific stages of a menstrual cycle or a pregnancy are compared to one or more threshold values associated with risk levels of certain health conditions and presented in the visualized data, wherein the one or more threshold values associated with risk levels of one or more health conditions are determined based on scientific research and data analysis in combination with a user's personalized data.

### Claim 13 (depends on 12)

The test system of claim 12, wherein the one or more health conditions include: a miscarriage, an ectopic pregnancy, an ovarian tumor, or an adrenal gland problem.

### Claim 14 (depends on 10)

The test system of claim 10, wherein the processor presents visualized data through the display including a comparison between the one or more T/C ratio trends or one or more quantitative hormone level trends and one or more normal hormone level trends.

### Claim 15 (depends on 10)

The test system of claim 10, wherein the visualized data presented through the display further includes an indication of a potential health condition risk derived from a comparison between the one or more T/C ratio trends or one or more quantitative hormone level trends and one or more normal hormone level trends.
